Zraik IM, Heß-Busch Y. Management of chemotherapy side effects and their long-term sequelae. Urol A. 2021;60:862–71. https://doi.org/10.1007/s00120-021-01569-7.

Article  Google Scholar 

Wang Z, Li H, Gou L, Li W, Wang Y. Antibody–drug conjugates: recent advances in payloads. Acta Pharm Sin B. 2023;13:4025–59. https://doi.org/10.1016/j.apsb.2023.06.015.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ponziani S, Di Vittorio G, Pitari G, Cimini AM, Ardini M, Gentile R, Iacobelli S, Sala G, Capone E, Flavell DJ, Ippoliti R, Giansanti F. Antibody-drug conjugates: the new frontier of chemotherapy. Int J Mol Sci. 2020;21:5510. https://doi.org/10.3390/ijms21155510.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Biomedicines | Free Full-Text | Advances and limitations of antibody drug conjugates for cancer. n.d. https://www.mdpi.com/2227-9059/9/8/872. Accessed 1 May 2024.

Xu X, Zhang J, Wang T, Li J, Rong Y, Wang Y, Bai C, Yan Q, Ran X, Wang Y, Zhang T, Sun J, Jiang Q. Emerging non-antibody-drug conjugates (non-ADCs) therapeutics of toxins for cancer treatment. Acta Pharm Sin B. 2023. https://doi.org/10.1016/j.apsb.2023.11.029.

Article  PubMed  PubMed Central  Google Scholar 

Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8:473–80. https://doi.org/10.1038/nrc2394.

Article  CAS  PubMed  Google Scholar 

Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates | Science. n.d. https://doi.org/10.1126/science.8327892. Accessed 1 May 2024.

Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;205:698–9. https://doi.org/10.1038/205698a0.

Article  CAS  PubMed  Google Scholar 

Paclitaxel (Taxol) | N Engl J Med. n.d. https://doi.org/10.1056/NEJM199504133321507. Accessed 1 May 2024.

Johnson DA, Laguzza BC. Antitumor xenograft activity with a conjugate of a vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1/D. Can Res. 1987;47:3118–22.

CAS  Google Scholar 

Dillman RO, Johnson DE, Shawler DL, Koziol JA. Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug1. Can Res. 1988;48:6097–102.

CAS  Google Scholar 

Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, Slichenmyer W. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol. 1999;17:478–478. https://doi.org/10.1200/JCO.1999.17.2.478.

Article  CAS  PubMed  Google Scholar 

Niell BL, Jochelson MS, Amir T, Brown A, Adamson M, Baron P, Bennett DL, Chetlen A, Dayaratna S, Freer PE, Ivansco LK, Klein KA, Malak SF, Mehta TS, Moy L, Neal CH, Newell MS, Richman IB, Schonberg M, Small W, Ulaner GA, Slanetz PJ. ACR Appropriateness Criteria® female breast cancer screening: 2023 update. J Am Coll Radiol. 2023;21(2024):S126–43. https://doi.org/10.1016/j.jacr.2024.02.019.

Article  Google Scholar 

Sharma P. Update on the treatment of early-stage triple-negative breast cancer. Curr Treat Opt Oncol. 2018;19:22. https://doi.org/10.1007/s11864-018-0539-8.

Article  Google Scholar 

Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer (Auckl). 2015;92s:BCBCR.S29420. https://doi.org/10.4137/BCBCR.S29420.

Article  Google Scholar 

Molecular portraits of human breast tumours | Nature. n.d. https://www.nature.com/articles/35021093. Accessed 9 June 2024.

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale A-L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001;98:10869–74. https://doi.org/10.1073/pnas.191367098.

Article  PubMed  PubMed Central  Google Scholar 

JCI—identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. n.d. https://www.jci.org/articles/view/45014?elq=2f1e11aad7e740cf9a3d8bfd51c3b4f4. Accessed 9 June 2024.

Wang D-Y, Jiang Z, Ben-David Y, Woodgett JR, Zacksenhaus E. Molecular stratification within triple-negative breast cancer subtypes. Sci Rep. 2019;9:19107. https://doi.org/10.1038/s41598-019-55710-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Soto JA, Wang X, Tominaga Y, Wang R-H, Cao L, Qiao W, Li C, Xu X, Skoumbourdis AP, Prindiville SA, Thomas CJ, Deng C-X. The inhibition and treatment of breast cancer with poly(ADP-ribose) polymerase (PARP-1) inhibitors. Int J Biol Sci. 2006;2:179–85.

Article  PubMed  PubMed Central  Google Scholar 

Hu X-C, Zhang J, Xu B-H, Cai L, Ragaz J, Wang Z-H, Wang B-Y, Teng Y-E, Tong Z-S, Pan Y-Y, Yin Y-M, Wu C-P, Jiang Z-F, Wang X-J, Lou G-Y, Liu D-G, Feng J-F, Luo J-F, Sun K, Gu Y-J, Wu J, Shao Z-M. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015;16:436–46. https://doi.org/10.1016/S1470-2045(15)70064-1.

Article  CAS  PubMed  Google Scholar 

TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer | J Clin Oncol. n.d. https://doi.org/10.1200/jco.2008.26.15_suppl.1009. Accessed 9 June 2024.

Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA, on behalf of the Translational Breast Cancer Research Consortium (TBCRC 011). Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res. 2013;19:5505–12. https://doi.org/10.1158/1078-0432.CCR-12-3327.

Article  CAS  PubMed  PubMed Central  Google Scholar 

β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells | PLoS ONE. n.d. https://doi.org/10.1371/journal.pone.0117097. Accessed 9 June 2024.

Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 2013;123:1348–58. https://doi.org/10.1172/JCI65416.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab | Breast Cancer | JAMA Oncology | JAMA Network. n.d. https://jamanetwork.com/journals/jamaoncology/article-abstract/2587051. Accessed 9 June 2024.

Nanda R, Chow LQM, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, Karantza V, Buisseret L. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 Study. J Clin Oncol. 2016;34:2460–7. https://doi.org/10.1200/JCO.2015.64.8931.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yin L, Duan J-J, Bian X-W, Yu S. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22:61. https://doi.org/10.1186/s13058-020-01296-5.

Article  PubMed  PubMed Central  Google Scholar 

Jeyachandran S, Chandrashekar K, Ganesan G, Alagarsamy L, Subbaraj GK, Kulanthaivel L. Triple-negative breast cancer (TNBC): clinical features and therapeutic targets. In: Pathak S, Banerjee A, Bisgin A, editors. Handbook of animal models and its uses in cancer research. Singapore: Springer Nature; 2022. p. 1–14. https://doi.org/10.1007/978-981-19-1282-5_41-1.

Chapter  Google Scholar 

Al Jarroudi O, El Bairi K, Curigliano G, Afqir S. Antibody–drug conjugates: a new therapeutic approach for triple-negative breast cancer. In: Al Jarroudi O, El Bairi K, Curigliano G, editors. Breast cancer research and treatment: innovative concepts. Cham: Springer International Publishing; 2023. p. 1–27. https://doi.org/10.1007/978-3-031-33602-7_1.

Chapter  Google Scholar 

Liu K, Li M, Li Y, Li Y, Chen Z, Tang Y, Yang M, Deng G, Liu H. A review of the clinical efficacy of FDA-approved antibody–drug conjugates in human cancers. Mol Cancer. 2024;23:62. https://doi.org/10.1186/s12943-024-01963-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody–drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18:3–19. https://doi.org/10.1158/1541-7786.MCR-19-0582.

Article  CAS  PubMed  Google Scholar 

Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? | Br J Cancer. n.d. https://www.nature.com/articles/bjc2017367. Accessed 7 June 2024.

Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9:33–46. https://doi.org/10.1007/s13238-016-0323-0.

Article  CAS  PubMed  Google Scholar 

Optimizing conjugation chemistry, antibody conjugation site, and surface density in antibody–nanogel conjugates (ANCs) for cell-specific drug delivery. Bioconjug Chem. 2023; 34707–718. https://doi.org/10.1021/acs.bioconjchem.3c00034.

King TA, Walsh SJ, Kapun M, Wharton T, Krajcovicova S, Glossop MS, Spring DR. Disulfide re-bridging reagents for single-payload antibody-drug conjugates. Chem Commun. 2023;59:9868–71. https://doi.org/10.1039/D3CC02980H.